Hydreight Technologies Inc
NURS.V
Toronto Stock Exchange Ventures3.49
CAD
+0.22
- -
ISIN
CA44877L1013
CUSIP
44877L101
Return %
Stock
S&P500
1Y
-13.83
15.01
3Y
1,103.45
82.56
5Y
1,645.00
79.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Shane Madden
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 7251 West Lake Mead Boulevard Las Vegas NV United States of America 89128
- IPO Date
- Feb 19, 2019
- Website
- hydreight.com
- Similar Companies
- Business
- Hydreight Technologies Inc. is a digital health infrastructure company that provides a proprietary telemedicine and direct-to-consumer healthcare platform, VSDHOne, enabling licensed healthcare professionals, nurses, doctors and med-spa operators to deliver services across the United States, with operations in all 50 states and principal executive offices in Vancouver, British Columbia, and Las Vegas, Nevada; the company was founded in 2018. Its platform includes integrated tools for booking, documentation, accounting, inventory, sales and patient data management, together with a medical network that includes nurses, physicians, telehealth enablement, pharmacy relationships and 503B pharmacy access. Hydreight’s core offerings include physician-supervised and telehealth-based treatments such as GLP-1 therapies, semaglutide-based programs, tirzepatide, liraglutide, NAD+ therapy, Sermorelin, Ipamorelin, hormone optimization, IV wellness, sexual health, hair restoration, personalized genetic testing, at-home STI testing and related wellness services. The company also supports pharmacy product sales and white-label/direct-to-consumer healthcare launches for partner brands, med-spa franchises and healthcare providers seeking compliant nationwide distribution and virtual care infrastructure. Recent strategic developments include an oversubscribed $15 million LIFE financing in January 2026, a $300,000 strategic investment in Insu Therapeutics in March 2026 to advance needle-free peptide delivery technology, expansion into the at-home STI testing market in December 2025, and the launch and continued scaling of peptide healthcare offerings following FDA advisory committee developments in July 2026. Hydreight is listed on the TSX Venture Exchange under NURS, and also trades on the OTCQB as HYDTF and on the Frankfurt Stock Exchange as SO6.